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Abstract
A literature review was conducted to evaluate and understand the effects of antidepressant medication during
pregnancy and the ethical issues surrounding the topic. Through the discussion of three articles, the review
weighed the effects of antidepressants on maternal and child health. Antidepressant medication during
pregnancy poses relative risks to cause fetal complications and defects, though the risk remains very small.
However, untreated depression may significantly impact the childbearing family, including premature births,
low birth weights, miscarriages, and suicide. Clinicians often have misconceptions of the risks of untreated
depression during pregnancy and could benefit from an increased understanding of the current literature
when making treatment decisions. Nevertheless, an individual’s history, symptomatology, and an
understanding of medications known to be harmful to the fetus should guide the choice of treatment. Further
research may help solidify understanding among clinicians and the public and ultimately lead to improved
health outcomes for both mother and child.
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Ritvanen, 2011).  Conversely, recent research indicates 
that the likelihood of birth defects after prenatal expo-
sure to certain psychiatric medications are not as great 
as earlier studies had estimated (“Prescribing During 
Pregnancy,” 2008).
An Ethical Issue
 The ethical question is whether or not to take 
antidepressant medications during pregnancy.  Re-
search indicates that antidepressants pose an increased 
risk to the fetus.  The research reviewed also indicates 
that untreated depression during pregnancy increases 
the rates of preterm births and substance abuse, both 
of which pose an increased risk to the fetus and the 
mother.  Thus, one must evaluate the risks and benefits 
in attempting to resolve the ethical situation.  
The Effects on Maternal and Child Health
 The article “Prescribing During Pregnancy” 
(2008) from the Harvard Medical School’s Harvard 
Mental Health Letter states that all psychiatric drugs 
cross the placenta and reach the developing fetus, and 
some increase the risk of certain congenital malforma-
tions.  Furthermore, Cohen et al. (2006) found that 
of 201 women with a history of Major Depressive 
Disorder (MDD), 68% of those who stopped taking 
antidepressants after becoming pregnant suffered a 
relapse of depression, compared to a 26% incidence of 
relapse in those who continued taking their antidepres-
sants.  Antenatal depression has been associated with 
low maternal weight gain, increased rates of preterm 
birth (Li, Liu, & Odouli, 2009), increased ambivalence 
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 Depression affects one quarter of women dur-
ing pregnancy (Cohen et al., 2006).  Clinical trials 
have demonstrated that medication and psychotherapy 
are effective as stand-alone forms of treatment for 
depression, yet a combination of the two treatment 
options provides the most sustained response.  But 
how does pharmacological treatment impact the fetus?  
Furthermore, what are the impacts of not treating the 
pregnant woman?  These are just a few of the ques-
tions that this paper will explore while examining the 
ethical issues surrounding the use of antidepressant 
drug therapy during pregnancy.  
Antidepressant Medications During Pregnancy
 Care must be taken when prescribing any 
medication during pregnancy and an evaluation of the 
risks and benefits to both the mother and fetus must 
be considered.  When life-threatening situations arise 
and require immediate intervention during pregnancy, 
it is common for “emergency” medications to be used.  
However, with conditions that pose less of an immedi-
ate threat to life, such as depression, medications are 
prescribed with greater hesitation (Payne &Meltzer-
Brody, 2009).  The body of literature suggests that 
common medications used to treat depression contrib-
ute to an increased risk including fetal heart defects, 
limb malformation, and persistent pulmonary hyper-
tension of the newborn (Malm, Artama, Gissler, & 
Vol 6, Iss 1, 2012-2013 Journal of Nursing Student Research 1
 A literature review was conducted to evaluate and understand the effects of antidepressant medication 
during pregnancy and the ethical issues surrounding the topic.  Through the discussion of three articles, the 
review weighed the effects of antidepressants on maternal and child health. Antidepressant medication dur-
ing pregnancy poses relative risks to cause fetal complications and defects, though the risk remains very small.  
However, untreated depression may significantly impact the childbearing family, including premature births, 
low birth weights, miscarriages, and suicide.  Clinicians often have misconceptions of the risks of untreated 
depression during pregnancy and could benefit from an increased understanding of the current literature when 
making treatment decisions.  Nevertheless, an individual’s history, symptomatology, and an understanding of 
medications known to be harmful to the fetus should guide the choice of treatment.  Further research may help 
solidify understanding among clinicians and the public and ultimately lead to improved health outcomes for 
both mother and child.   
1
Schmidt: Antidepressant Drug Therapy
Published by ScholarlyCommons, 2013
about the pregnancy and overall worsened health (Orr, 
Blazer, James, & Reiter, 2007). Additionally, prenatal 
exposure to maternal stress has demonstrated conse-
quences for the development of infant temperament 
(Davis et al., 2005). 
Literature Review
Antidepressant Use During Pregnancy: 
Current Controversies and Treatment Strategies
 In this article, Payne and Meltzer-Brody (2009) 
examined the risks and benefits of antidepressant use 
during pregnancy.  Initially addressed is the “common 
misconception” that MDD is “different from, and not 
as serious as, medical illness.”  This often results in in-
appropriate discontinuation of antidepressants during 
pregnancy.  Payne et al (2009) asserted that continu-
ation of medication should revolve around symptom-
atology, where patients with mild MDD might discon-
tinue therapy and more severe MDD may benefit from 
continued therapy due to known risks of untreated 
depression.
 Next, the authors discussed how the litera-
ture offers limited evidence to guide clinical practice 
regarding antidepressant therapy in the pregnant 
woman and the inability to randomly assign depressed 
pregnant women in clinical trials and the resultant 
unknowns from limited data. They also referred to the 
limited helpfulness of the FDA Pregnancy Categories, 
including that “1) the FDA categories do not address 
dosing; 2) lack of consideration of time of exposure 
to the medication; and 3) excessive reliance on animal 
data and lack of human data” (Payne and Meltzer-
Brody, 2009).  The authors concluded that the safety 
of antidepressant use during pregnancy appears to 
be reassuring, however state that two topics remain 
unclear: neonatal withdrawal syndrome and primary 
pulmonary hypertension of the newborn (PPHN).
SSRI during pregnancy and risk of persistent pul-
monary hypertension in the newborn
 Kieler et al. (2012) showed that exposure to 
SSRI late in pregnancy was associated with an in-
creased risk of PPHN.  Specifically, they concluded 
that the risk was double that of the general popula-
tion.  This translates to 3 babies in every 1000 born 
having PPHN versus 1 in every 1000 in the general 
population.  It should be noted that although this is an 
increased risk relative to the general population, the 
overall risk is relatively low.  Furthermore, there are 
other known causes of PPHN including asthma, dia-
betes, and obesity.  These factors were not part of the 
exclusionary criteria for analysis in the study and thus 
it is difficult to determine if it was the medication or 
these other medical conditions that affected the data.  
Prenatal drug exposure and an untreated psychiatric 
disorder both present risks
 This article reviews the risks of both prenatal 
psychotropic drug exposure and untreated psychiatric 
disorder, though the primary focus of this publication 
was antidepressants and specifically SSRIs. An antide-
pressant that should not be used during pregnancy is 
paroxetine because it might increase the risk of several 
types of rare congenital heart defects if used during the 
first trimester.  Furthermore, when used during the last 
trimester of pregnancy, SSRIs as a class of medica-
tions that demonstrate temporary problems in as many 
as 25% of newborns, with common symptoms of 
tremors, restlessness, mild respiratory problems, and 
weak crying. “Prescribing During Pregnancy” (author, 
2008) reveals that “in most cases, these symptoms dis-
appear in the first few days after birth, although some 
infants are admitted to the neonatal intensive care unit 
as a precaution.”  
Putting Theory into Practice
Recommended Changes in Practice
 Based on the current research regarding anti-
depressant use during pregnancy, [as future clinicians, 
it is important to think of developing evidence based 
guidelines that address the needs of this vulnerable 
population] {my initial goal as a nurse would be to 
work to create evidence-based guideline.}guidelines.  
By creating guidelines for the use of antidepressants 
during pregnancy, clinicians may provide increasingly 
consistent information and care to pregnant women.  
Though additional research will solidify treatment 
approaches based on looming questions, the litera-
ture does offer a start to creating  guidelines.  First, 
medications that are known to cause fetal harm should 
not be used.  Second, an establishment of treatment 
criteria based on the severity of the symptoms should 
guide usage.  Third, the guidelines should include in-
formation about the risks of abruptly stopping medica-
tion and the increased risk of usage of medication late 
in pregnancy.  A nurse may immediately implement all 
of these into practice to educate, support and inform 
patients, leading to improved levels of care.  Further-
more, attempts to increase awareness of clinicians by 
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hosting educational meetings and journal clubs may 
ensure that care reflects the current literature.  Chal-
lenging the misconception that MDD during pregnan-
cy is relatively benign to the fetus and woman serves 
as a starting point to enhancing clinical options and 
outcomes. 
Barriers to Recommendation
 Challenges and barriers exist in implementing 
these recommendations. Challenges include the will-
ingness of the clinical team to acknowledge and ac-
cept the literature enough to motivate change in their 
practice.  Furthermore, a comprehensive meta-analysis 
of the literature needs to be synthesized to create a 
more uniform understanding of and therefore trust in 
the treatment of pregnant women with MDD.  Barriers 
that exist include limited knowledge regarding fetal 
risk of untreated MDD in pregnancy, and the short and 
long-term risks to the fetus of antidepressant exposure 
during pregnancy.  Confronting these issues remains 
difficult because research involving pregnant women 
in placebo-controlled trials is currently protected. 
Conclusion and Opinion 
 To best determine the choice of treatment, 
the nurse should use the current literature to guide 
practice.  This includes educating the patient on the 
risks with a nomenclature that is not misleading.  For 
example, the research shows that using SSRIs dur-
ing the late stages of pregnancy increases “relative 
risk” of PPHN and is (statistically) “significant.”  This 
could imply a false risk versus the truth: that the risk 
goes from 1 in 1000 births to 3 in 1000 births.  There-
fore, as additional information becomes available and 
eventually resolves conflicting information regarding 
the use of antidepressants, the better choices clini-
cians and patients will have.  Thus, it is important that 
researchers receive adequate funding so that clinicians 
may better understand the risks and benefits of utiliz-
ing antidepressant medication as a treatment option 
during pregnancy.
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